Gilead revises remdesivir access for COVID-19, used PPE test negative for virus — top stories in infectious disease
Click Here to Manage Email Alerts
The top story in infectious disease last week was about Gilead’s new process for requesting the investigational antiviral remdesivir as a possible therapy for patients with COVID-19.
Another top story was about a study that showed personal protective equipment (PPE) used by health care workers treating patients with SARS-CoV-2 tested negative for the virus.
Read these and more of last week’s top stories in infectious disease below:
Gilead revises access to remdesivir for COVID-19 amid surge in demand
Gilead Sciences said it cannot accept new compassionate use requests for its investigational antiviral remdesivir due to “overwhelming demand” from physicians hoping to repurpose the drug as a potential therapy for patients with COVID-19, but there are still ways to get access to the medication. Read more.
Swabbed PPE worn during COVID-19 patient care test negative for virus
PPE, including goggles, N95 respirators and shoes, worn by health care workers caring for patients with SARS-CoV-2 tested negative for the virus, according to a recent study. Read more.
Researchers examine 69 existing drugs for efficacy against COVID-19
A team of researchers from around the world have identified 69 different drugs and compounds, including FDA-approved agents, compounds in clinical trials and preclinical compounds, that they are examining for potential effectiveness in SARS-CoV-2 infection assays. Read more.
Experts say US surpassing Italy, China in COVID-19 cases was inevitable
The United States now leads the world in the total number of confirmed COVID-19 cases, surpassing China and Italy by thousands. Read more.
AlloVir, Baylor collaborate to develop COVID-19 T-cell therapy
AlloVir, a clinical stage T-cell immunotherapy company, will work with Baylor College of Medicine to develop allogeneic, virus-specific T-cell therapy to combat COVID-19, according to a news release. Read more.